Galectin Therapeutics (GALT) Assets Average (2011 - 2026)

Galectin Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• In Q1 2026, Assets Average rose 30.6% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.6 million (up 30.6% YoY), while the FY2025 annual figure was $18.5 million, down 18.97% from the prior year.
• Assets Average was $17.6 million for Q1 2026 at Galectin Therapeutics, up from $16.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $37.7 million in Q1 2022 to a low of $12.6 million in Q2 2025.
• Historically, Assets Average has averaged $22.1 million across 5 years, with a median of $21.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Assets Average soared 43.71% in 2022, then sank 53.07% in 2025.
• A 5-year view of Assets Average shows it stood at $19.6 million in 2022, then rose by 28.48% to $25.2 million in 2023, then retreated by 7.74% to $23.2 million in 2024, then sank by 30.28% to $16.2 million in 2025, then rose by 8.93% to $17.6 million in 2026.
• The last three Assets Average figures came in at $17.6 million (Q1 2026), $16.2 million (Q4 2025), and $14.2 million (Q3 2025), per Business Quant data.